Ocular Therapeutix, Inc. $OCUL Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 71.2% during the 1st quarter, Holdings Channel reports. The fund owned 26,987 shares of the biopharmaceutical company’s stock after selling 66,675 shares during the period. SG Americas Securities LLC’s holdings in Ocular Therapeutix were worth $229,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Cantor Fitzgerald L. P. acquired a new stake in shares of Ocular Therapeutix during the 3rd quarter worth about $2,360,000. Avoro Capital Advisors LLC lifted its stake in shares of Ocular Therapeutix by 38.5% during the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after buying an additional 2,850,000 shares during the period. Empire Life Investments Inc. lifted its stake in shares of Ocular Therapeutix by 115.0% during the fourth quarter. Empire Life Investments Inc. now owns 540,115 shares of the biopharmaceutical company’s stock valued at $6,557,000 after buying an additional 288,853 shares during the period. Assenagon Asset Management S.A. boosted its position in Ocular Therapeutix by 1,261.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 620,814 shares of the biopharmaceutical company’s stock worth $7,537,000 after acquiring an additional 575,214 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $3,800,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at approximately $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 28,999 shares of company stock worth $237,792. Insiders own 3.10% of the company’s stock.

Ocular Therapeutix Trading Down 3.2%

OCUL traded down $0.34 on Friday, reaching $10.20. 1,875,627 shares of the company’s stock were exchanged, compared to its average volume of 3,074,943. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The company’s 50 day moving average is $9.19 and its 200-day moving average is $9.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -6.99 and a beta of 0.88.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on OCUL shares. Robert W. Baird boosted their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.